Treatment Of Acute Deep Vein Thrombosis Of The Lower Ext

该研究的目的是评估使用重组组织型纤溶酶原激活剂（rtPA）溶栓治疗下肢急性深静脉血栓的效果。虽然传统的抗凝治疗在预防危及生命的肺栓塞方面非常有效，但它并不能保护受影响腿部的静脉功能，往往会在随后的几年里导致静脉后综合征。该研究旨在评估这种治疗方式的有效性、安全性和成本，以恢复下肢静脉功能。自研究开始以来，已有14名患者接受了治疗。除一名患者外，其他患者均有明显改善。只有两名患者在治疗期间有小肺栓塞的证据，这是在所有接受治疗的患者中获得的通气灌注肺扫描中发现的。这些患者均无临床症状。一名患者出现了不危及生命的二头肌血肿，可能是在rtPA治疗期间自动血压监测引起的。没有患者需要输血，也没有发生其他并发症。

The objective of the study is to evaluate thrombolytic therapy using recombinant tissue plasminogen activator (rtPA) for treatment of acute deep vein thrombosis of the lower extremity. While the conventional therapy, anticoagulation alone, is highly effective in prevention of life threatening pulmonary embolism, it does not preserve venous function in the affected leg, often leading to postphlebitic syndromes in subsequent years. The study is designed to evaluate efficacy, safety, and cost of this form of treatment for restoration of venous function in the lower extremity. Since start of the study, 14 patients have been treated. All except one patient had significant improvement. Only two patients have had evidence of small pulmonary emboli during treatment, detected on ventilation perfusion lung scans that are obtained in all patients accepted into the protocol. None of these patients were clinically symptomatic. One patient developed a non-life-threatening biceps hematoma probably induced by automatic blood pressure monitoring during the rtPA treatment. No patients have required blood transfusions and no other complications have occurred.